The article "The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart".
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645541 | PMC |
| http://dx.doi.org/10.1007/s10557-019-06929-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mitochondria-targeted fluorescent probe for visualization of exogenous and endogenous methylglyoxal in living cells.
Chem Commun (Camb)
May 2022
Tianjin Key Laboratory for Photoelectric Materials and Devices, and Key Laboratory of Display Materials & Photoelectric Devices, Ministry of Education, School of Materials Science & Engineering, Tianjin University of Technology, Tianjin, 300384, China.
An activatable mitochondria-targeted fluorescent probe Hcy-OPD was synthesized for the detection of methylglyoxal (MGO). For the introduction of a preorganized isopropylamino group on the aromatic -diamine framework to regulate the hindrance effect, Hcy-OPD showed high selectivity and sensitivity (0.22 μM) for monitoring MGO.
View Article and Find Full Text PDFTargeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide.
Nutrients
April 2021
Department of Diabetes, Central Clinical, School, Alfred Medical Research and Education Precinct, Monash University, Melbourne, VIC 3004, Australia.
Diabetic kidney disease (DKD) remains the number one cause of end-stage renal disease in the western world. In experimental diabetes, mitochondrial dysfunction in the kidney precedes the development of DKD. Reactive 1,2-dicarbonyl compounds, such as methylglyoxal, are generated from sugars both endogenously during diabetes and exogenously during food processing.
View Article and Find Full Text PDFCorrection to: The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.
Cardiovasc Drugs Ther
April 2020
Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
The article "The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart".
View Article and Find Full Text PDFThe Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart.
Cardiovasc Drugs Ther
December 2019
Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Purpose: Methylglyoxal, a by-product of glycolysis and a precursor in the formation of advanced glycation end-products, is significantly elevated in the diabetic myocardium. Therefore, we sought to investigate the mitochondria-targeted methylglyoxal scavenger, MitoGamide, in an experimental model of spontaneous diabetic cardiomyopathy.
Methods: Male 6-week-old Akita or wild type mice received daily oral gavage of MitoGamide or vehicle for 10 weeks.
A mitochondria-targeted mass spectrometry probe to detect glyoxals: implications for diabetes.
Free Radic Biol Med
February 2014
MRC Mitochondrial Biology Unit, Wellcome Trust/MRC Building, Cambridge CB2 0XY, UK. Electronic address:
The glycation of protein and nucleic acids that occurs as a consequence of hyperglycemia disrupts cell function and contributes to many pathologies, including those associated with diabetes and aging. Intracellular glycation occurs after the generation of the reactive 1,2-dicarbonyls methylglyoxal and glyoxal, and disruption of mitochondrial function is associated with hyperglycemia. However, the contribution of these reactive dicarbonyls to mitochondrial damage in pathology is unclear owing to uncertainties about their levels within mitochondria in cells and in vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!